{"preliminary_commentary":{"by_channel":{"x_thread":11,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03802604\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["talimogene laherparepvec","atezolizumab"]],"indication":"residual HER2-negative breast cancer after neoadjuvant chemotherapy","name":"PROMETEO","nct_id":"NCT03802604","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=prometeo-nct03802604. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PROMETEO","arms":[{"description":"1. Talimogene laherparepvec: Cycle 1 - 10\\^6 PFU/mL. Cycle 2, 3, 4 \\& 5 - 10\\^8 PFU/mL.\n2. Atezolizumab 840 mg","label":"Talimogene laherparepvec + Atezolizumab","type":"EXPERIMENTAL"}],"collaborators":["Amgen","Roche Pharma AG"],"completion_date":{"date":"2025-03-18","type":"ACTUAL"},"conditions":["Breast Cancer"],"enrollment":{"count":28,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Talimogene laherparepvec","otherNames":["T-VEC","Imlygic"],"type":"BIOLOGICAL"},{"name":"Atezolizumab","otherNames":["Tecentric"],"type":"DRUG"}],"last_update":"2025-09-09","lead_sponsor":"SOLTI Breast Cancer Research Group","official_title":"Combination of Talimogene Laherparepvec With Atezolizumab in Patients With Residual Breast Cancer After Standard Neoadjuvant Multi-agent Chemotherapy (PROMETEO TRIAL)","overall_status":"COMPLETED","phases":["EARLY_PHASE1"],"primary_completion_date":{"date":"2022-04-27","type":"ACTUAL"},"primary_outcomes":[{"measure":"Rate of residual cancer burden class 0 and 1 (RCB0/1)","timeFrame":"24 months since first patient in"}],"references":[{"citation":"Pascual T, Vidal M, Cejalvo JM, Vega E, Sanfeliu E, Villacampa G, Ganau S, Parreno AMJ, Zamora E, Miranda I, Delgado A, Bermejo B, Segui E, Braso-Maristanty F, de la Cruz-Merino L, Juan M, Galvan P, Gonzalez-Farre X, Chillara S, Villagrasa P, Pfefferle AD, O'Connell CE, Ferrero-Cafiero JM, Oliveira M, Perou CM, Prat A. Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO). Nat Commun. 2026 Feb 16;17(1):2817. doi: 10.1038/s41467-026-69222-5.","pmid":"41698899","type":"DERIVED"},{"citation":"Pascual T, Cejalvo JM, Oliveira M, Vidal M, Vega E, Ganau S, Julve A, Zamora E, Miranda I, Delgado A, Bermejo B, la Cruz-Merino L, Juan M, Ferrero-Cafiero JM, Canes J, Gonzalez X, Villagrasa P, Prat A. SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. Future Oncol. 2020 Aug;16(24):1801-1813. doi: 10.2217/fon-2020-0246. Epub 2020 Jul 7.","pmid":"32633563","type":"DERIVED"}],"start_date":{"date":"2018-12-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer","url":"https://clinicaltrials.gov/study/NCT03802604"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/prometeo-nct03802604"}